EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›GNVR

GNVR

Genvor Inc

Next earnings ≈ Aug 11, 2026 · est. from filing cadence

Hold
$0.50
▲ 0.00%
$0.50▲ +124900.00%
over 1Y
L $0.00EODHDH $2.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+0.0%
1M+9.1%
3M-36.9%
YTD-61.5%
1Y+124900.0%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
F
Valuation
Fair value
Filings
Flagged
Hold
Conviction
Horizon
Medium (3–12mo)

High return on equity (425.9%).

Revenue (FY2021) $0.00 · FY2021

Genvor Inc shows $0.00 in FY2021 revenue, and 425.9% ROE.

Financials · annual, by fiscal year

Line itemFY20FY21FY23FY24FY25
Revenue$0.00$0.00———
Gross profit—————
Operating income—-$3.10M-$1.44M-$2.78M-$6.41M
Net income-$4.87K-$3.44M-$1.71M-$2.88M-$5.59M
Diluted EPS——-$0.09-$0.15-$0.22
Net margin—————

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$17.2M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-32.4%
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt$20.0K
Net cash$17.2K
Altman Z-Score-1288.65 distress
Piotroski F-Score3/8

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+75.9%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — restated periodic report (2026-03-13). Worth a closer look.
  1. 8-K Material agreement2026-06-22
  2. 8-K Officer / director change2026-05-21
  3. 10-Q Quarterly report2026-05-13
  4. 8-K Unregistered share sales2026-05-11
  5. 8-K Material agreement2026-04-22
  6. 10-Q/A Restated periodic report2026-03-13
  7. 10-Q Quarterly report2026-02-12
  8. 10-K Annual report2025-12-10
  9. 10-K/A Restated periodic report2025-09-09

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-172026-06-22open ↗3Period ending 2026-05-182026-05-26open ↗8-KPeriod ending 2026-05-182026-05-21open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-052026-05-11open ↗8-KPeriod ending 2026-04-162026-04-22open ↗4Period ending 2026-04-152026-04-16open ↗4Period ending 2026-04-072026-04-14open ↗10-Q/APeriod ending 2025-12-312026-03-13open ↗10-QPeriod ending 2025-12-312026-02-12open ↗4Period ending 2026-01-092026-01-09open ↗10-KPeriod ending 2025-09-302025-12-10open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
GrowthF
Profitability—
Financial healthF
Momentum—
  • ✗Profitable (positive net income)
  • ✓Liabilities below 2× equity
Revenue
$0.00
Net margin
—
ROE
—
P/E
—

SEC fundamentals · FY 2025

■ revenue · ■ net income, by fiscal year

Revenue$0.00
Net income-$5.59M-93.7%
Operating income-$6.41M-130.3%
Diluted EPS-$0.22-46.7%
Cash & equivalents$37.2K+9881.5%
Total assets$45.8K+28.8%
Total liabilities$1.36M-22.4%
Stockholders' equity-$1.31M+23.4%
L/E: -1.03x

Frequently asked

Is Genvor Inc (GNVR) a buy?
GNVR currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (425.9%).
What is Genvor Inc's quality score?
GNVR scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001792941, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 9:46:05 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-04-15
Pawlak Chad Lee Sr.
Chief Executive Officer
Award250K @ $0.50$125K
2026-04-07
Pawlak Chad Lee Sr.
Chief Executive Officer
Award250K
2026-01-09
Pawlak Chad Lee Sr.
Chief Executive Officer
Award250K
2025-12-02
Jaynes Jessee M
Chief Research Officer
Award124K @ $1.50$186K
2025-10-08
Pawlak Chad Lee Sr.
Chief Executive Officer
Award250K
2025-07-01
Pawlak Chad Lee Sr.
Chief Executive Officer
Award250K
2025-05-08
Jaynes Jessee M
Chief Research Officer
Award400K @ $0.25$100K
2025-05-08
Yates Clayton Clopton
Director
Award400K @ $0.25$100K
2025-05-02
Pawlak Chad Lee Sr.
Chief Executive Officer
Award500K @ $0.25$125K
2024-04-25
Pawlak Chad Lee Sr.
Chief Executive Officer
Award25.0K
2024-04-25
Pawlak Chad Lee Sr.
Chief Executive Officer
Award4.88M
2024-04-17
Pawlak Chad Lee Sr.
Chief Executive Officer
Award25.0K

Recent news

market news →
Life Sciences Virtual Investor Forum Agenda Announced for December 11thBullish
globenewswire.com· 2025-12-09
Genvor and Tuskegee University Announce Teaming Agreement to Advance Peptide Research and Sustainable Crop Protection TechnologiesBullish
globenewswire.com· 2025-12-02
Genvor Restores Trading Status and Expands Global Collaborative Research NetworkBullish
globenewswire.com· 2025-10-09

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score19 vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5